• 1. An ionic liquid-based synergistic extraction strategy for rare earths?
  Yingbo Li,Nada Mehio,Huizhou Liu,Sheng Dai Green Chem., 2015,17, 2981-2993
• 2. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 3. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 4. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 5. Ambient electrochemical NH3 synthesis from N2 and water enabled by ZrO2 nanoparticles?
  Tong Xu,Dongwei Ma,Chengbo Li,Qian Liu,Siyu Lu,Abdullah M. Asiri,Chun Yang,Xuping Sun Chem. Commun., 2020,56, 3673-3676

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Research Brief on 2-Chloro-4,5-difluorobenzoic Acid (CAS: 110877-64-0) in Chemical and Biomedical Applications

2-Chloro-4,5-difluorobenzoic acid (CAS: 110877-64-0) is a fluorinated benzoic acid derivative that has garnered significant attention in recent years due to its versatile applications in pharmaceutical synthesis, agrochemical development, and material science. This compound serves as a key intermediate in the synthesis of various bioactive molecules, particularly those targeting enzyme inhibition and receptor modulation. Recent studies have highlighted its potential in the design of novel anti-inflammatory, antimicrobial, and anticancer agents, owing to its unique physicochemical properties imparted by the chloro and difluoro substitutions on the aromatic ring.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2-chloro-4,5-difluorobenzoic acid as a building block for the development of selective COX-2 inhibitors. The researchers utilized this compound to synthesize a series of derivatives that exhibited potent anti-inflammatory activity with reduced gastrointestinal side effects compared to traditional NSAIDs. The presence of the difluoro moiety was found to enhance metabolic stability and improve bioavailability, making it a promising candidate for further preclinical evaluation.

In the field of antimicrobial research, a team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters (2024) that derivatives of 2-chloro-4,5-difluorobenzoic acid showed remarkable activity against multidrug-resistant Staphylococcus aureus (MRSA) strains. The compound's ability to disrupt bacterial cell wall synthesis was attributed to its optimal lipophilicity, achieved through the strategic halogen and fluorine substitutions. This finding opens new avenues for addressing the growing challenge of antibiotic resistance.

From a synthetic chemistry perspective, recent advancements in green chemistry have explored more sustainable routes for producing 2-chloro-4,5-difluorobenzoic acid. A 2024 ACS Sustainable Chemistry & Engineering publication detailed a novel biocatalytic method using engineered fluorinases that significantly reduced the environmental impact of traditional halogenation processes while maintaining high yield and purity. This development is particularly relevant for scaling up production while adhering to increasingly stringent environmental regulations.

The compound's potential in materials science was highlighted in a 2023 Advanced Materials study, where 2-chloro-4,5-difluorobenzoic acid was incorporated into liquid crystal polymers. The resulting materials exhibited exceptional thermal stability and electro-optical properties, suggesting applications in flexible electronics and display technologies. The researchers noted that the specific substitution pattern of this derivative provided an optimal balance between molecular rigidity and fluidity.

Looking forward, several clinical trials are anticipated to begin in 2025 evaluating drug candidates derived from 2-chloro-4,5-difluorobenzoic acid, particularly in oncology and autoimmune disease indications. The compound's versatility as a synthetic intermediate, combined with its favorable ADME (Absorption, Distribution, Metabolism, and Excretion) profile when incorporated into larger molecules, positions it as a valuable tool in modern drug discovery pipelines. Future research directions may explore its use in PROTAC (Proteolysis Targeting Chimera) technology and other targeted protein degradation approaches.

• 501008-42-0(2,5-Dichloro-3-fluorobenzoic acid)
• 2252-51-9(2-Chloro-4-fluorobenzoic acid)
• 150444-93-2(2-Chloro-3,4-difluorobenzoic acid)
• 103877-61-8(2-chloro-5-fluoro-4-methylbenzoic Acid)
• 102940-86-3(2-Chloro-3-fluorobenzoic acid)
• 2252-50-8(2-Chloro-5-fluorobenzoic acid)
• 112062-61-0(Benzoic acid, 2,3-dichloro-4,5-difluoro-)
• 115549-04-7(5-Fluoro-2,3,4-trichlorobenzoic acid)
• 232275-55-7(2,6-Dichloro-4-fluorobenzoic acid)
• 1261956-79-9(2-Chloro-4-(3,4-difluorophenyl)benzoic acid)